A Phase 3 interventional study of Insulin Glargine and Sitagliptin in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 16 sites in 16 countries. Open to participants aged 35 Years to 71 Years. Per ClinicalTrials.gov, last updated 2012-10-04.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 118th largest by enrollment of the 175 interventional ones that give a count, is one of 10 that started in 2009, is one of 60 in phase 3, and was the 61st registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 18+
Loyola University · Sites in United States
Ages 18+ · Women only
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 30–65
Yanbing Li
Ages 18–70
By country, each count listing its studies:
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 35 Years to 71 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 10 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 253 across the 175 interventional studies. Of the 161 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 176 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
186 studies in Diabetes Mellitus, Type 2 by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 183 finished, 46 (25%) have results posted.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 136th largest by enrollment of the 178 interventional ones that give a count, is one of 15 that started in 2009, is one of 80 in phase 3, and was the 68th registered.
Sanofi’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
1 of the studies testing Insulin Glargine in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 186 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was the extension of the LANTU_C_02761 study named EASIE and identified as NCT00751114 (core study comparing insulin glargine versus sitagliptin in insulin-naïve patients treated with metformin and not adequately controlled).
All patients with Glycosylated Hemoglobin A1c (HbA1c) ≥ 7% at the end of the core study had the possibility to enter this extension study if they met the other inclusion criteria and did not present with any exclusion criteria.
The visit 14 of the core study (week 24) was the visit 1 (baseline, week 0) of the extension study which consisted of a 12-week treatment period.
The objectives of this extension study were:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Insulin glargine administered once a day, in the evening, at dinner or at bedtime. Starting dose: - last dose administered in the core study for patients previously treated with insulin glargine, - 0.2 U/Kg of body weight for patients previously treated with sitagliptin. Monitoring of blood glucose and titration: all patients, irrespective of their previous treatment group in the core study were empowered to adjust their insulin doses, under strict investigator's supervision. The goal was to achieve through a force titration 70 \< Fasting Plasma Glucose (FPG) ≤ 100 mg/dL (3.9 \<FPG ≤ 5.5 mmol/L). Sitagliptin: stable dose of 100 mg once a day administered with or without food.
Drug: Insulin Glargine · Drug: Sitagliptin · Drug: Metformin
Subcutaneous injection. 100 Units/mL solution for injection in a prefilled SoloStar® pen (3 mL).
Also known as: Lantus®
Oral administration. 100mg film-coated tablets.
Also known as: Januvia®
Patients continued with metformin as usual oral anti-diabetic treatment.
HbA1c Response Rate: Percentage of Patients Achieving Glycosylated Haemoglobin A1c (HbA1c) < 7% at Study Endpoint (End of Treatment Period)
Time frame: study endpoint: week 12 or earlier in case of premature discontinuation
HbA1c: Change From Baseline to Study Endpoint
Change = study endpoint - baseline
Time frame: baseline, study endpoint: week 12 or earlier in case of premature discontinuation
Self-Monitored Fasting Plasma Glucose (SMFPG) Mean : Change From Baseline to Study Endpoint
SMFPG mean = mean of the fasting plasma glucose values recorded on the 6 consecutive days before the visit (at least 3 values needed). Change = study endpoint - baseline.
Time frame: baseline, study endpoint: week 12 or week 8 if value not available at week 12
7-point Plasma Glucose Profile: Change From Baseline to Study Endpoint
7-point plasma glucose recorded before and after breakfast, before and after lunch, before and after dinner and at bedtime. Change = study endpoint - baseline.
Time frame: baseline, study endpoint: week 12 or week 8 if value not available at week 12
Insulin Dose
Daily dose at the face-to-face visits
Time frame: baseline, week 4, week 8, week 12
Number of Patients With at Least One Episode of Symptomatic Hypoglycemia
Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia confirmed or not by a plasma glucose measurement \<= 70mg/dL \[3.9 mmol/L\]
Time frame: During the treatment period (12 weeks) plus 7 days after last dose
Change in Body Weight From Baseline to Study Endpoint
Change = study endpoint - baseline
Time frame: baseline, study endpoint: week 12 or week 8 or week 4 depending on last available value
Among the 445 patients who completed the EASIE study, 194 had an endpoint Glycosylated Hemoglobin A1c (HbA1c) ≥ 7%. A total of 112 patients were included in the extension study: 37 uncontrolled on previous treatment with metformin and insulin glargine and 75 uncontrolled on previous treatment with metformin and sitagliptin in the EASIE study.
| Milestone | Combination Insulin Glargine and Sitagliptin |
|---|---|
| Started | 112 |
| Safety population | 112 |
| Treated by combination | 111 |
| Modified intent-to-treat population | 111 |
| Completed | 110 |
| Not completed | 2 |
| Withdrew: Withdrawal by subject | 2 |
| percentage of participants | Combination Insulin Glargine and Sitagliptin |
|---|---|
| HbA1c Response Rate: Percentage of Patients Achieving Glycosylated Haemoglobin A1c (HbA1c) < 7% at Study Endpoint (End of Treatment Period) | 51.9 (41.97 to 61.70) |
Change = study endpoint - baseline
| percent | Combination Insulin Glargine and Sitagliptin |
|---|---|
| HbA1c: Change From Baseline to Study Endpoint | -0.80 ± 1.05 |
SMFPG mean = mean of the fasting plasma glucose values recorded on the 6 consecutive days before the visit (at least 3 values needed). Change = study endpoint - baseline.
| mg/dL | Combination Insulin Glargine and Sitagliptin |
|---|---|
| Self-Monitored Fasting Plasma Glucose (SMFPG) Mean : Change From Baseline to Study Endpoint | -35.43 ± 39.61 |
7-point plasma glucose recorded before and after breakfast, before and after lunch, before and after dinner and at bedtime. Change = study endpoint - baseline.
| mg/dL | Combination Insulin Glargine and Sitagliptin |
|---|---|
| Before breakfast (N=104) | -34.2 ± 38.1 |
| After breakfast (N=103) | -34.1 ± 48.1 |
| Before lunch (N=104) | -26.6 ± 48.2 |
| After lunch (N=104) | -26.5 ± 43.7 |
| Before dinner (N=103) | -25.1 ± 43.0 |
| After dinner (N=100) | -24.9 ± 46.7 |
| At bedtime (N=93) | -35.2 ± 51.7 |
Daily dose at the face-to-face visits
| unit per kg body weight | Combination Insulin Glargine and Sitagliptin |
|---|---|
| Baseline | 0.28 ± 0.18 |
| Week 4 N=110 | 0.37 ± 0.16 |
| Week 8 N=110 | 0.42 ± 0.18 |
| Week 12 | 0.46 ± 0.20 |
Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia confirmed or not by a plasma glucose measurement \<= 70mg/dL \[3.9 mmol/L\]
| participants | Combination Insulin Glargine and Sitagliptin |
|---|---|
| Number of Patients With at Least One Episode of Symptomatic Hypoglycemia | 40 |
Change = study endpoint - baseline
| kg | Combination Insulin Glargine and Sitagliptin |
|---|---|
| Change in Body Weight From Baseline to Study Endpoint | 1.15 ± 2.24 |
Collected over Adverse events were assessed throughout the extension study (12 weeks). Only adverse events starting from inclusion in the extension study were taken into account.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Combination Insulin Glargine and Sitagliptin | — | 2/112 (1.8%) | 0/112 (0%) |
| Event | Combination Insulin Glargine and Sitagliptin |
|---|---|
| Right ventricular failureCardiac disorders | 1/112 |
| Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/112 |
| Age Continuous(years) | Combination Insulin Glargine and Sitagliptin |
|---|---|
| Mean | 52.4 ± 9.3 |
| Sex: Female, Male(Participants) | Combination Insulin Glargine and Sitagliptin |
|---|---|
| Female | 56 |
| Male | 55 |
| Body Weight(kg) | Combination Insulin Glargine and Sitagliptin |
|---|---|
| Mean | 84.6 ± 21.0 |
| Body Mass Index(kg/m²) | Combination Insulin Glargine and Sitagliptin |
|---|---|
| Mean | 31.3 ± 5.2 |
| Systolic Blood Pressure(mmHg) | Combination Insulin Glargine and Sitagliptin |
|---|---|
| Mean | 129.9 ± 15.5 |
| Diastolic Blood Pressure(mmHg) | Combination Insulin Glargine and Sitagliptin |
|---|---|
| Mean | 80.1 ± 7.3 |
| Heart Rate(beats/min) | Combination Insulin Glargine and Sitagliptin |
|---|---|
| Mean | 76.9 ± 9.1 |
| Duration of diabetes(years) | Combination Insulin Glargine and Sitagliptin |
|---|---|
| Median | 4.1 ± 5.1 |
4 further baseline measures are reported on the registry.
The record gives a start of Jun 2009, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin Glargine · Sitagliptin · Metformin